Abstract
To clarify the effect of fibroblast growth factor-21 (FGF-21) on islet transplantation, a suboptimal number of islets were transplanted into streptozotocin (STZ)-induced diabetic mice with or without FGF-21 treatment. Three-day treatment with FGF-21 contributed to restoration of normoglycemia by suppressing islet graft loss. The FGF-21-treated mice showed lower glycemic levels despite similar insulin content in the graft than that in untreated mice on day 3, indicating that FGF-21 not only has a cytoprotective effect but also decreases β-cell load by increasing insulin sensitivity. These results suggest that FGF-21 may be useful as a treatment to improve islet engraftment rates in clinical islet transplantation.
Publication types
-
Evaluation Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Blood Glucose / analysis
-
Blood Glucose / drug effects
-
Blood Glucose / metabolism
-
Diabetes Mellitus, Experimental / metabolism
-
Diabetes Mellitus, Experimental / physiopathology
-
Diabetes Mellitus, Experimental / therapy
-
Fibroblast Growth Factors / pharmacology*
-
Fibroblast Growth Factors / therapeutic use
-
Glucose Tolerance Test
-
Insulin / blood
-
Insulin / metabolism
-
Insulin Secretion
-
Islets of Langerhans / drug effects
-
Islets of Langerhans / metabolism
-
Islets of Langerhans / physiopathology
-
Islets of Langerhans Transplantation / methods*
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Models, Animal
-
Streptozocin
-
Transplantation Conditioning / methods
-
Transplantation, Isogeneic
Substances
-
Blood Glucose
-
Insulin
-
fibroblast growth factor 21
-
Streptozocin
-
Fibroblast Growth Factors